Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Along with GLP-1 drugs Zepbound and Mounjaro, sales also climbed for Taltz, a psoriasis treatment, and breast-cancer drug Verzenio. Including Thursday's moves, Lilly's stock has risen 10.6% in ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Analysts expect more than $18 billion in sales from Mounjaro this year and over $10 billion from Zepbound, which was recently approved in the United States as a treatment for some forms of sleep ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Analysts expect more than $18 billion in sales from Mounjaro this year and over $10 billion from Zepbound, which was recently approved in the United States as a treatment for some forms of sleep ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.